A Phase I, Multi Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD9164 Given Once Daily as Inhaled Formulation Via Turbuhaler for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease (COPD).
Phase of Trial: Phase I
Latest Information Update: 18 Nov 2010
At a glance
- Drugs AZD 9164 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- 18 Nov 2010 Planned End Date changed from 1 Jul 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.
- 28 Jun 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 19 May 2010 Official Title amended as reported by ClinicalTrials.gov.